Curis (CRIS) H.C. Wainwright 27th Annual Global Investment Conference summary

Strategic focus and leadership

• Emavusertib, a first-in-class IRAK4 inhibitor, is prioritized for its broad application in lymphoma, leukemia, and solid tumors, with proof-of-concept data in PCNSL and AML showing significant improvement over standard care.

• Leadership team brings over 20 years of experience each, with recent addition of Dr. Ahmed Hamdy to drive CLL development.

Mechanism of action and clinical rationale

• Emavusertib blocks TLR and FLT3 pathways in AML, and TLR in CLL/NHL, complementing BTK inhibitors for deeper responses.

• Combination with BTK inhibitors targets both BCR and TLR pathways, showing synergistic tumor reduction and deeper responses in preclinical data.

Market landscape and unmet needs

• BTK inhibitors revolutionized NHL but have drawbacks: incomplete responses, lifelong therapy, and side effects.

• BCL2/anti-CD20 therapies offer fixed-duration treatment but have challenging safety profiles and have not displaced BTK inhibitors.